Palvella Therapeutics (PVLA) Notes Payables (2024 - 2025)
Palvella Therapeutics (PVLA) posted quarterly Notes Payables of $2.2 million for Q4 2025, up 11.02% year-over-year from $2.0 million in Q4 2024, and down 0.9% quarter-over-quarter from $2.2 million in Q3 2025.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Notes Payables (2024 - 2025) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Notes Payables for 2 consecutive years, with $2.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Notes Payables rose 11.02% year-over-year to $2.2 million; the TTM figure through Dec 2025 stood at $2.2 million (up 11.02% YoY), while the FY2025 annual figure was $2.2 million, up 11.02% from the prior year.
- Notes Payables slipped to $2.2 million in Q4 2025 per PVLA's latest filing, from $2.2 million in the prior quarter.
- Across five years, Notes Payables topped out at $2.2 million in Q3 2025 and bottomed at $2.0 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 2.22 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 1.98 Mn |